Drug delivery modifier Corium International files for a $50 million IPO
Corium International, a commercial stage pharmaceutical company that adapts drugs to wearable delivery systems, filed on Monday with the SEC to raise up to $50 million in an initial public offering. The Menlo Park, CA-based company, which was founded in 1995 and booked $48 million in sales for the 12 months ended December 31, 2013, plans to list on the NASDAQ under the symbol CORI. Corium initially filed confidentially on December 23, 2013. Jefferies and Leerink Partners are the joint bookrunners on the deal. No pricing terms were disclosed.